Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

Bibliography

• Christopher R. A cannabis chronology. Available from: www.ukcia.org
   Google Scholar
• Russo EB. History of cannabis and its preparations in saga, science and sobriquet. Chem Biodivers 2007;4:1614-48
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147:S163-71
   PubMed Web of Science ®Google Scholar
• Fleming MP, Clarke RC. Physical evidence for the antiquity of Cannabis sativa L. J Int Hemp Assoc 1998;5:80-92
   Google Scholar
• World Drug Report 2008. Cannabis market. Available from: www.undoc.org/documents/wdr/WDR_2008/WDR2008_Cannabis_market.pdf
   Google Scholar
• Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7
   Web of Science ®Google Scholar
• Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007;369:1047-53
   PubMed Web of Science ®Google Scholar
• Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict 2007;16:331-42
   PubMed Web of Science ®Google Scholar
• Vandrey RG, Budney AJ, Hughes JR, A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco and both substances. Drug Alc Depend 2008;92(1-3):48-54
   PubMed Web of Science ®Google Scholar
• Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009;23:543-53
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis:relation to use, abuse, dependence. Int Rev Psychiatry 2009;21:104-12
   PubMed Web of Science ®Google Scholar
• Mechoulam R. Marihuana chemistry. Science 1970;168:1159-63
   PubMed Web of Science ®Google Scholar
• Devane WA, Dysarz FA, Johnson MR, Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13
   PubMed Web of Science ®Google Scholar
• Henquet C, Krabbendam L, Spauwen J, Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br Med J 2005;330:11
   PubMed Web of Science ®Google Scholar
• Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psych 2004;161:1967-77
   PubMed Web of Science ®Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV). American Psychiatric Association 1994
   Google Scholar
• International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) 2007. Available from: http://apps.who.int/classifications/apps/icd/icd10online/
   Google Scholar
• Haney M, Hart CL, Vosburg SK, Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharm 2004;29:158-70
   PubMed Web of Science ®Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders, proposed draft of the fifth Edition (DSM-5). American Psychiatric Association 2010. Available from: www.dsm.org
   Google Scholar
• Machado Rocha FC, Stefano SC, De Cassia Haiek R, Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care 2008;17:431-43
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397-411
   PubMed Web of Science ®Google Scholar
• Available from: http://who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf
   Google Scholar
• Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998;30:187-96
   PubMed Web of Science ®Google Scholar
• Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010;105:494-503
   PubMed Web of Science ®Google Scholar
• Montalban X, Sastre Garriga J, Vila C, Clissold SP. THC and CBD oromucosal spray (Sativex ) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurotherapeutics 2011; accepted for publication
   Google Scholar
• Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today 2006;42:495-501
   PubMed Web of Science ®Google Scholar
• Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30:271-80
   PubMed Web of Science ®Google Scholar
• Di Marzo V. The endocannabinoid system for the development of new drugs for spasticity. Drugs Future 2007;32:341-51
   Web of Science ®Google Scholar
• Zuardi AW, Crippa JA, Hallak JE, Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39:421-9
   PubMed Web of Science ®Google Scholar
• Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234-46
   PubMed Web of Science ®Google Scholar
• Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007;17:347-61
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of delta-9-THC and cannabidiol on nocturnal sleep and early morning behaviour in young adults. J Clin Psychopharmacol 2004;24:305-13
   PubMed Web of Science ®Google Scholar
• Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur J Neurol 2008;15(Suppl 3):365
   Google Scholar
• Guy GW, Robson P. A Phase-1, double blind, three-way crossover study to assess the pharmacokinetic profile of Cannabis Based Medicinal Extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy volunteers. J Cannabis Ther 2003;3:121-52
   Google Scholar
• Sativex® integrated safety analysis, 2008. Data on file, GW Pharma
   Google Scholar
• Sativex® integrated safety analysis, 2010. Data on file, GW Pharma
   Google Scholar
• Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Goodman LS, Murad F, editors, The Pharmacological Basis of Therapeutics. 7th edition. Macmillan, New York; 1985
   Google Scholar
• Tart CT. Marijuana intoxication: common experiences. Nature 1970;226:701-4
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45
   PubMed Web of Science ®Google Scholar
• Wade D, Makela P, Robson P, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, ; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; doi: 10.1111/j.1468-1331.2010.03328.x
   Google Scholar
• Notcutt W, Davies P, Langford R, Ratcliffe S. Results of a randomised withdrawal study of subjects with spasticity due to multiple sclerosis who were receiving long-term Sativex®. Mult Scler 2009;15:S258
   PubMed Web of Science ®Google Scholar
• Schoedel K, Chen N, Guy GW, Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. Eur Neuropsychopharmacol 2010;20(Suppl 3):S587
   Google Scholar
• Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict 2008;17:161-4
   PubMed Web of Science ®Google Scholar
• Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007;4:4-16
   PubMedGoogle Scholar
• Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacol 2009;56(Suppl 1):235-43
   PubMedGoogle Scholar